Eighty stakeholders from twenty major biomedical research institutions across the globe have agreed upon a list of 19 open science practices to be implemented and monitored. The study, led by Dr. Kelly Cobey, Scientist and Director of the Open Science and Meta Research Program at the University of Ottawa Heart Institute, Canada, forms the basis for the future development of institutional digital dashboards that will display that institution's compliance with open science practices.

A team of researchers at the University of Wisconsin­-Madison has successfully combined genomics with machine learning in the quest to develop accessible tests that allow earlier detection of cancer.

For many types of cancer, early detection can lead to better outcomes for patients. While scientists are developing new blood tests that analyze DNA to aid in earlier detection, these new technologies have limitations, including cost and sensitivity.

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as an "article in press" in the Journal of the American College of Surgeons (JACS) and presented at the Southern Surgical Association 134th Annual Meeting in December 2022.

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and 80 years of age with a significant history of smoking, or who currently smoke. Lung cancer screening with LDCT has been shown to reduce death from lung cancer by up to 24 percent.

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it a promising technology for various medical treatments in the future.

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist in a tiny percentage of the cells.

Current DNA mutation software detectors, while scanning the 3 billion bases of the human genome, are not well suited to discern mosaic mutations hiding among normal DNA sequences.

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how the innovative standard is used to enable the flow of health information. FHIR apps can pull in data from most electronic health record systems, facilitating secure movement of information when and where needed.